LUNAC THERAPEUTICS LIMITED
Company number 11317849 · Monitor this company
The annual accounts for this company are overdue.
The confirmation statement for this company is overdue.
Free AI analysis
Have an AI read this company's filings and write an assessment — financial health, risks, and what the numbers say.
Shareholders' funds
-£9,397,757
Balance sheet as at 2024-05-31
Overview
- Company type
- Private Limited Company
- Incorporated
- 2018-04-18
- Registered office
- 29 Craven Street, London, WC2N 5NT
- Postcode
- WC2N 5NT
- Capital
- 4 GBP
- Accounts category
- Small
Accounts
- Last made up to
- 2024-05-31
- Next due by
- 2026-02-28 Overdue
- Financial year end
- 31 May
Confirmation statement
- Last statement dated
- 2025-04-17
- Next due by
- 2026-05-01 Overdue
Nature of business (SIC)
- 72190 Other research and experimental development on natural sciences and engineering
Officers 4 current · 3 resigned
Group structure
Controlled by Caribou Property Ltd (01804545) — since 2020-05-06
Controlled by EPIDAREX CAPITAL III UK, LP — since 2019-09-20
From persons-with-significant-control filings on the public register.
Contact details
- Website
- lunactherapeutics.com
LUNAC Therapeutics are a drug discovery spin-out from University of Leeds, developing next generation oral anti-coagulant therapies.
The class of 2018
38%
of the 541 companies in this sector incorporated in 2018 are still active today; 58% have since been dissolved.
A fact about the year, not a forecast for this company.